Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus RENOVUE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus RENOVUE 65.
IOPAMIDOL-370 IN PLASTIC CONTAINER vs RENOVUE-65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, low-osmolality radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing the contrast of vascular structures and tissues during imaging. It does not have a specific molecular target but relies on its iodine content for radiopacity.
Iothalamate meglumine is an ionic, high-osmolality iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It acts by increasing the radiopacity of blood vessels and organs during imaging.
Intravenous: 0.5-2 mL/kg (185-740 mg iodine/kg) as a single dose; repeated doses may be administered up to a total of 5 mL/kg (1850 mg iodine/kg) within a 24-hour period.
Intravenous injection, 10 mL (6.48 g iobitridol) as a single dose. Repeat dosing: up to 3 additional doses within 30 minutes, maximum 40 mL per procedure.
None Documented
None Documented
Terminal half-life 1.5–2 hours in normal renal function; prolonged to 4–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2.0 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <10 mL/min).
Renal: >90% unchanged by glomerular filtration within 24–48 hours; biliary/fecal: <2%.
Renal: 100% as unchanged drug; no biliary or fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent